Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Correlation Between Surrogate Endpoints And Overall Survival In Unresectable Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review And Meta-analysis.

Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

Litao Huang1,2, Deying Kang2,3, Chongyang Zhao3

  • 1Chinese Evidence-Based Medicine Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Scientific Reports
|February 21, 2024

Related Experiment Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K

View abstract on PubMed

Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) show limited utility of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in unresectable hepatocellular carcinoma (uHCC). Complete response (CR) strongly correlates with OS, offering better predictive value.

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trial Analysis

Background:

  • Unresectable hepatocellular carcinoma (uHCC) presents therapeutic challenges.
  • Immune checkpoint inhibitors (ICIs) are a key treatment modality for uHCC.
  • Evaluating surrogate endpoints for overall survival (OS) is crucial for efficient clinical trial design.

Approach:

  • Systematic literature review of phase I-III clinical trials for uHCC treated with ICIs.
  • Meta-regression analyses to assess correlations between OS and surrogate endpoints like progression-free survival (PFS) and complete response (CR).
  • Surrogate Threshold Effect (STE) calculation and subgroup analyses to refine endpoint utility.

Key Points:

  • Progression-free survival (PFS) demonstrated a weak correlation with overall survival (OS) (R²=0.352).
Keywords:
Hepatocellular carcinomaImmunologyMeta-analysisSurvival

Related Experiment Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K
  • Complete response (CR) showed a strong correlation with OS (R²=0.905).
  • Phase III trials and ICI + intra-arterial (IA) combinations revealed significant correlations between OS and various endpoints, including stable disease (SD) and immune-related adverse events (irAEs).

    • Conclusions:

    • Complete response (CR) is a more reliable surrogate endpoint for overall survival (OS) than PFS in uHCC patients treated with ICIs.
    • Subgroup analyses, particularly in phase III trials and ICI + IA combinations, provide nuanced insights into endpoint validity.
    • Findings aid in interpreting clinical trial outcomes and selecting appropriate endpoints for future uHCC immunotherapy studies.